strategic-management

246 VIJAYA NARAPAREDDY
EXHIBIT 4 Revenues by Business and Geographical Segment
(In millions of $) U.S. INTERNATIONAL
Year ended Dec. 31, 2008 2007 2006 2008 2007 2006
Pharmaceuticals $ 18,851 $ 21,548 $ 24,503 $ 25,323 $ 22,876 $ 20,580
Animal Health 1,168 1,132 1,032 1,657 1,507 1,279
Corporate/Other 416 473 287 881 882 690
TOTAL $ 20,435 $ 23,153 $ 25,822 $ 27,861 $ 25,265 $ 22,549
ANNUAL PERCENTAGE CHANGES
WORLDWIDE TOTALS US INTERNATIONAL
% CHANGE 2008/07 2007/06 2008/07 2007/06 2008/07 2007/06
Pharmaceuticals (1) (1) (13) (12) 11 11
Animal Health 7 14 3 10 10 18
Corporate/Other — — (12) (10) 10 12
Source: Pfizer Annual Report (2008).
EXHIBIT 5 Pfizer’s Income Statement (in thousands)
PERIOD ENDING 31-Dec-08 31-Dec-07 31-Dec-06
Total Revenue $48,296,000 48,418,000 48,371,000
Cost of Revenue 8,112,000 11,239,000 7,640,000
Gross Profit 40,184,000 37,179,000 40,731,000
Operating Expenses
Research Development 7,945,000 8,089,000 7,599,000
Selling General and Administrative 14,537,000 15,626,000 15,589,000
Non Recurring 3,308,000 2,817,000 2,158,000
Others 2,668,000 3,128,000 3,261,000
Total Operating Expenses 28,458,000 29,660,000 28,607,000
Operating Income or Loss 11,726,000 7,519,000 12,124,000
Income from Continuing Operations
Total Other Income/Expenses Net (1,516,000) 2,156,000 1,392,000
Earnings Before Interest and Taxes 10,210,000 9,675,000 13,516,000
Interest Expense 516,000 397,000 488,000
Income Before Tax 9,694,000 9,278,000 13,028,000
Income Tax Expense 1,645,000 1,023,000 1,992,000
Minority Interest (23,000) (42,000) (12,000)
Net Income from Continuing Ops 8,026,000 8,213,000 11,024,000
Non-recurring Events
Discontinued Operations 78,000 (69,000) 8,313,000
Extraordinary Items — — —
Effect of Accounting Changes — — —
Other Items — — —
Net Income 8,104,000 8,144,000 19,337,000
Preferred Stock and Other Adjustments — — —
Net Income Applicable to Common Shares $ 8,104,000 $ 8,144,000 $ 19,337,000
Source: Pfizer’s 2008 Form 10k.